Navigation Links
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
Date:11/4/2008

also be at increased risk of developing a number of long-term health consequences, including obesity, insulin resistance, carbohydrate intolerance, dyslipidemia, and psychosocial disadvantages. If untreated, SGA children account for nearly 15 percent of short adults.

In conjunction with this indication approval, and in support of the Novo Nordisk Triple Bottom Line; a commitment to economic success, environmental soundness, and social responsibility to employees and customers; the company will donate up to $15,000 to local charities in New Jersey, where the company has its U.S. headquarters.

"For 40 years, Novo Nordisk has helped to make children's lives better through an unwavering commitment to the field of endocrinology and growth-related disorders," said Eddie Williams, Vice President, Biopharmaceuticals, at Novo Nordisk. "In the past two years, Novo Nordisk has made Norditropin(R) available to a wider range of patients through the approval of three indications: treatment of children with short stature associated with Noonan syndrome, treatment of children with short stature associated with Turner syndrome, and now, the treatment of patients born SGA."

About SGA

Children born SGA are born shorter and/or weigh less than 97 percent of children of the same gestational age, regardless of whether or not they are born premature. SGA may be caused by fetal abnormalities, placental insufficiency, and maternal factors.

The natural growth hormone level of children born SGA varies from normal to deficient. Decreased growth is likely due to insensitivity to the body's own growth hormone and/or other growth factors. Growth hormone therapy is thought to overcome this insensitivity, enabling children to reach their full height potential.

About Norditropin(R)

Norditropin(R) (somatropin [rDNA origin] injection) is indicated for the treatment of children with short stature associated with Noonan syndrome, treatment of children with
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves Durameds LoSEASONIQUE(R) Oral Contraceptive
2. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
3. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
4. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
5. FDA Approves Fougeras Clotrimazole Cream USP 1%
6. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
7. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
8. Signalife Board Approves Merger
9. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
10. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
11. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015   GenoSpace , a leading ... and analysis of genomic and other biomedical data, ... joined the company as Vice President of Sales ... "GenoSpace partners with its ... analyze and explore complex sets of genomic, phenotypic ...
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on ... current state of the global Propanol market with a focus on the Chinese situation. ... Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang ...
(Date:7/30/2015)... Diego , CA (PRWEB) , ... July 30, ... ... announced the successful completion of a field clinical study of its canine osteoarthritis ... developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed in ...
(Date:7/30/2015)... July 30, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... today reported financial results for the second quarter 2015. ... 2015, we remain on track to achieve our commercial ... Executive Officer of the Company. "Since our last quarterly ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... Mich., July 8 GeneGo, Inc., the leading,systems biology ... GeneGo products. Unilever uses systems analysis tools for,research in ... "Unilever was one of GeneGo,s first customers in Europe, ... said Julie Bryant, GeneGo,s VP,of Business development. "Unilever is ...
... Metabolex, Inc., a,biopharmaceutical company focused on the ... treatment of metabolic diseases,announced that it has promoted ... and Robert Martin to Vice President of Project ... development in our company,in support of our expanding ...
... Md., July 7 ActiPatch(TM), the,product marketed by Bioelectronics ... and the way we heal. Recently chosen as "One ... MedicalHeadway.com,ActiPatch is fast becoming the treatment of choice for ... decision to include ActiPatch in the top 9 medical ...
Cached Biology Technology:Unilever Extends Their GeneGo MetaCore License 2Metabolex Names Zhao, Martin to Executive Posts 2BioElectronic's ActiPatch(TM) Product Chosen as 'One of 9 Medical Breakthroughs That May Change Your Life' 2BioElectronic's ActiPatch(TM) Product Chosen as 'One of 9 Medical Breakthroughs That May Change Your Life' 3BioElectronic's ActiPatch(TM) Product Chosen as 'One of 9 Medical Breakthroughs That May Change Your Life' 4
(Date:7/23/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2015.  Revenue for ... of 33% compared to $6.8 million in the same quarter ... was $0.3 million, or $0.01 per diluted share, which compared ... same period a year ago.  Lower revenue ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
(Date:7/21/2015)... NEW YORK , July 21, 2015 /PRNewswire/ ... critical systems, as seen in the recent U.S. ... enterprises a solution to the infosec conundrum, but ... data is stored. To address this dilemma, Biometrics-as-a-Service ... of its Biometric Tokenization SDK for third party ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... and ecological sustainability of biofuels and the impact of ... America will take place on Friday, Dec. 5, in ... Neotropical Forests: Trends, Implications and Emerging Alternatives, is sponsored ... the Program in Native Species Reforestation, both joint programs ...
... Associated Professor, DSc Barbara Ann Halkier, Department of ... Life Sciences, University of Copenhagen, has been granted ... award for her excellent research into secondary metabolites, ... plants. In particular, her research has focused ...
... Company Experiences Record Revenue Growth from Operations in Third Quarter , ... bioMETRX, Inc. (OTC Bulletin Board: BMRX), a leading developer of consumer-based ... ending September 30, 2008. , , ... 430% increase over second quarter revenues of $100,000. , ...
Cached Biology News:Conference to explore sustainability of biofuels 2The Danisco Award 2008 goes to D.Sc. Barbara Ann Halkier from Faculty of Life Sciences, Copenhagen 2bioMETRX, Inc. Highlights 3rd Quarter 2008 Financial Results 2